Cargando…

Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial

BACKGROUND: Hypoxia-inducible-factor-1α (HIF-1α) and HIF-1 degrading prolyl-hydroxylases (PHD) are key regulators of the hypoxic-inflammatory response. Functionally active genetic variants in the HIF-1α (C/T; Single Nucleotide Polymorphism (SNP) rs11549465) and the PHD2 gene (EGLN1; C/T; SNP rs51665...

Descripción completa

Detalles Bibliográficos
Autores principales: Höcker, Annika, Rabeling, Miriam, Bick, Alexandra, Cox, Linda, Kreuzer, Maximiliane, Engler, Andrea, Walstein, Kai, Bachmann, Hagen S., Jöckel, Karl-Heinz, Eisele, Lewin, Adamzik, Michael, Peters, Jürgen, Schäfer, Simon T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982006/
https://www.ncbi.nlm.nih.gov/pubmed/27515179
http://dx.doi.org/10.1186/s12871-016-0225-y
_version_ 1782447693090521088
author Höcker, Annika
Rabeling, Miriam
Bick, Alexandra
Cox, Linda
Kreuzer, Maximiliane
Engler, Andrea
Walstein, Kai
Bachmann, Hagen S.
Jöckel, Karl-Heinz
Eisele, Lewin
Adamzik, Michael
Peters, Jürgen
Schäfer, Simon T.
author_facet Höcker, Annika
Rabeling, Miriam
Bick, Alexandra
Cox, Linda
Kreuzer, Maximiliane
Engler, Andrea
Walstein, Kai
Bachmann, Hagen S.
Jöckel, Karl-Heinz
Eisele, Lewin
Adamzik, Michael
Peters, Jürgen
Schäfer, Simon T.
author_sort Höcker, Annika
collection PubMed
description BACKGROUND: Hypoxia-inducible-factor-1α (HIF-1α) and HIF-1 degrading prolyl-hydroxylases (PHD) are key regulators of the hypoxic-inflammatory response. Functionally active genetic variants in the HIF-1α (C/T; Single Nucleotide Polymorphism (SNP) rs11549465) and the PHD2 gene (EGLN1; C/T; SNP rs516651 and T/C; SNP rs480902) are associated with altered HIF-1α mRNA nuclear translocation and an altered adaptation to hypoxia. Furthermore, the HIF system is important in surviving inflammatory disorders and sepsis. Thus, we tested the hypotheses, that SNPs in the HIF-1α or PHD2 genes are (1) common in Caucasians, with 2) the HIF-1α genetic variant being associated with an altered HIF-1α mRNA expression; and 3) independent risk factors for 30-day mortality in severe sepsis. METHODS: After ethics approval, 128 septic patients (Caucasian descent) were included prospectively within 24 h after first diagnosing sepsis. Patients characteristics and severity of illness (simplified acute physiology score II), genotypes (Taqman assay), and their influence on leukocyte HIF-1α-mRNA-expression (Real-Time PCR) and 30-day mortality were determined. RESULTS: Frequencies were 0.8 % for homozygous HIF-1α TT-carriers (CT 17.6 %; CC 81.6 %), 2.5 % for homozygous PHD2 SNP rs516651 TT-allele carriers (CT 17.5 % and CC 80 %), and 9.4 % for homozygous PHD2 SNP rs480902 TT-allele carriers (CT 34.4 % and CC 56.3 %). While HIF-1α T-allele carriers had a borderline decrease in HIF-1α-mRNA-expression (p = 0.06) neither HIF-1α nor PHD2 SNPs were (independent) risk factors for 30-day mortality. CONCLUSIONS: Genetic variants in HIF-1α and PHD2 genes exist in Caucasians but do not appear to alter 30-day mortality in sepsis.
format Online
Article
Text
id pubmed-4982006
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49820062016-08-13 Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial Höcker, Annika Rabeling, Miriam Bick, Alexandra Cox, Linda Kreuzer, Maximiliane Engler, Andrea Walstein, Kai Bachmann, Hagen S. Jöckel, Karl-Heinz Eisele, Lewin Adamzik, Michael Peters, Jürgen Schäfer, Simon T. BMC Anesthesiol Research Article BACKGROUND: Hypoxia-inducible-factor-1α (HIF-1α) and HIF-1 degrading prolyl-hydroxylases (PHD) are key regulators of the hypoxic-inflammatory response. Functionally active genetic variants in the HIF-1α (C/T; Single Nucleotide Polymorphism (SNP) rs11549465) and the PHD2 gene (EGLN1; C/T; SNP rs516651 and T/C; SNP rs480902) are associated with altered HIF-1α mRNA nuclear translocation and an altered adaptation to hypoxia. Furthermore, the HIF system is important in surviving inflammatory disorders and sepsis. Thus, we tested the hypotheses, that SNPs in the HIF-1α or PHD2 genes are (1) common in Caucasians, with 2) the HIF-1α genetic variant being associated with an altered HIF-1α mRNA expression; and 3) independent risk factors for 30-day mortality in severe sepsis. METHODS: After ethics approval, 128 septic patients (Caucasian descent) were included prospectively within 24 h after first diagnosing sepsis. Patients characteristics and severity of illness (simplified acute physiology score II), genotypes (Taqman assay), and their influence on leukocyte HIF-1α-mRNA-expression (Real-Time PCR) and 30-day mortality were determined. RESULTS: Frequencies were 0.8 % for homozygous HIF-1α TT-carriers (CT 17.6 %; CC 81.6 %), 2.5 % for homozygous PHD2 SNP rs516651 TT-allele carriers (CT 17.5 % and CC 80 %), and 9.4 % for homozygous PHD2 SNP rs480902 TT-allele carriers (CT 34.4 % and CC 56.3 %). While HIF-1α T-allele carriers had a borderline decrease in HIF-1α-mRNA-expression (p = 0.06) neither HIF-1α nor PHD2 SNPs were (independent) risk factors for 30-day mortality. CONCLUSIONS: Genetic variants in HIF-1α and PHD2 genes exist in Caucasians but do not appear to alter 30-day mortality in sepsis. BioMed Central 2016-08-11 /pmc/articles/PMC4982006/ /pubmed/27515179 http://dx.doi.org/10.1186/s12871-016-0225-y Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Höcker, Annika
Rabeling, Miriam
Bick, Alexandra
Cox, Linda
Kreuzer, Maximiliane
Engler, Andrea
Walstein, Kai
Bachmann, Hagen S.
Jöckel, Karl-Heinz
Eisele, Lewin
Adamzik, Michael
Peters, Jürgen
Schäfer, Simon T.
Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial
title Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial
title_full Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial
title_fullStr Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial
title_full_unstemmed Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial
title_short Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial
title_sort hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982006/
https://www.ncbi.nlm.nih.gov/pubmed/27515179
http://dx.doi.org/10.1186/s12871-016-0225-y
work_keys_str_mv AT hockerannika hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial
AT rabelingmiriam hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial
AT bickalexandra hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial
AT coxlinda hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial
AT kreuzermaximiliane hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial
AT englerandrea hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial
AT walsteinkai hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial
AT bachmannhagens hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial
AT jockelkarlheinz hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial
AT eiselelewin hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial
AT adamzikmichael hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial
AT petersjurgen hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial
AT schafersimont hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial